Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Limin ZhangTao JiangXuefei LiYan WangChao ZhaoSha ZhaoLei XiShijia ZhangXiaozhen LiuYijun JiaHui YangJinpeng ShiChunxia SuShengxiang RenCaicun ZhouPublished in: Cancer (2017)
The Bim deletion polymorphism was found to be associated with poor clinical response to crizotinib in patients with ALK fusion-positive NSCLC. Cancer 2017;123:2927-35. © 2017 American Cancer Society.